NDC 0023-3670-90 Aczone
Dapsone Gel Topical

Package Information

The NDC Code 0023-3670-90 is assigned to a package of 1 tube in 1 carton > 90 g in 1 tube of Aczone, a human prescription drug labeled by Allergan, Inc.. The product's dosage form is gel and is administered via topical form.

Field Name Field Value
NDC Code 0023-3670-90
Package Description 1 TUBE in 1 CARTON > 90 g in 1 TUBE
Product Code 0023-3670
Proprietary Name What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
Aczone
Non-Proprietary Name What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
Dapsone
Usage Information Product Usage Information
The drug use information is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate. This information is not individual medical advice and does not substitute for the advice of a health care professional. Always ask a health care professional for complete information about this product and your specific health needs.
This medication is used to treat acne. It helps decrease the number and severity of acne pimples and helps pimples that do develop to heal more quickly. Dapsone is an antibiotic. It is not known how dapsone works to treat acne.
11-Digit NDC Billing Format NDC Format for Billing
For insurance billing purposes the Centers for Medicare & Medicaid Services (CMS) created an 11 digit NDC derivative identifier. If the NDC Package code is less than 11 digits the code must be padded with leading zeros. The leading zeros must be added to the appropriate segment to create a 5-4-2 configuration.
00023367090
Billing Unit GM - Billing unit of "gram" is used when a product is measured by its weight.
Estimated Billable Units per Package 90 GM
NADAC Wholesale Price per Unit National Average Drug Acquisition Cost (NADAC)
The National Average Drug Acquisition Cost (NADAC) wholesale price per unit for NDC 0023-3670-90 is $9.65199 and is up-to-date as of 01-13-2021. This product is billed per "GM" gram and contains an estimated amount of 90 billable units per package. The estimated wholesale price for the this package based on the lastest NADAC pricing survey is $
$9.65199
NDC to RxNorm Crosswalk
  • RxCUI: 607295 - dapsone 5 % Topical Gel
  • RxCUI: 607295 - dapsone 0.05 MG/MG Topical Gel
  • RxCUI: 701858 - Aczone 5 % Topical Gel
  • RxCUI: 701858 - dapsone 0.05 MG/MG Topical Gel [Aczone]
  • RxCUI: 701858 - Aczone 0.05 MG/MG Topical Gel
  • Product Type What kind of product is this?
    Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
    Human Prescription Drug
    Labeler Name Allergan, Inc.
    Dosage Form Gel - A semisolid3 dosage form that contains a gelling agent to provide stiffness to a solution or a colloidal dispersion.4 A gel may contain suspended particles.
    Administration Route(s)
    • Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.
    Active Ingredient(s)
    Pharmacologic Class(es)
    Sample Package Sample Package?
    This field Indicates whether this package is a sample packaging or not.
    No
    Marketing Category What is the Marketing Category?
    Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
    NDA - A product marketed under an approved New Drug Application.
    FDA Application Number What is the FDA Application Number?
    This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
    NDA021794
    Start Marketing Date What is the Start Marketing Date?
    This is the date that the labeler indicates was the start of its marketing of the drug product.
    06-24-2009
    Listing Expiration Date What is the Listing Expiration Date?
    This is the date when the listing record will expire if not updated or certified by the product labeler.
    12-31-2022
    Exclude Flag What is the NDC Exclude Flag?
    This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".
    N
    NDC Code Structure

    The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

    * Please review the disclaimer below.

    Other Product Packages

    The following packages are also available for Aczone with product NDC 0023-3670.

    NDC Package CodePackage Description
    0023-3670-0315 TUBE in 1 CARTON > 3 g in 1 TUBE
    0023-3670-301 TUBE in 1 CARTON > 30 g in 1 TUBE
    0023-3670-601 TUBE in 1 CARTON > 60 g in 1 TUBE

    * Please review the disclaimer below.